<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The neuroprotective effects of NBQX (2,3-dihydroxy-6-<z:chebi fb="13" ids="29785">nitro</z:chebi>-7-<z:chebi fb="0" ids="48266">sulfamoyl</z:chebi>-benzo(f)<z:chebi fb="0" ids="36616">quinoxaline</z:chebi>) were assessed on hippocampal CA1 <z:hpo ids='HP_0002529'>neuronal loss</z:hpo> and locomotor <z:hpo ids='HP_0000752'>hyperactivity</z:hpo> following transient bilateral carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp> (BCAO) in the gerbil </plain></SENT>
<SENT sid="1" pm="."><plain>NBQX, a selective blocker of the AMPA <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> receptor subtype, was injected 1 h after 5 or 10 min BCAO, or sham surgery </plain></SENT>
<SENT sid="2" pm="."><plain>Both 5 and 10 min <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> produced equivalent <z:hpo ids='HP_0000752'>hyperactivity</z:hpo> 3 days post <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and CA1 <z:hpo ids='HP_0002529'>neuronal loss</z:hpo> on Day 4, while activity was unchanged in the sham-operated group </plain></SENT>
<SENT sid="3" pm="."><plain>NBQX protected from both hippocampal damage and post-ischemic <z:hpo ids='HP_0000752'>hyperactivity</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>These results demonstrate that NBQX can protect from behavioral pathology induced by global <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>